CRIS Current Research Information System

MALAGOLA, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.524
AS - Asia 2.034
EU - Europa 1.820
AF - Africa 140
SA - Sud America 99
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 3
Totale 6.623
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.505
SG - Singapore 556
CN - Cina 552
VN - Vietnam 524
GB - Regno Unito 492
SE - Svezia 297
DE - Germania 227
IT - Italia 225
FR - Francia 129
HK - Hong Kong 128
RU - Federazione Russa 93
IN - India 91
UA - Ucraina 78
IE - Irlanda 71
BR - Brasile 64
TG - Togo 51
NL - Olanda 45
JP - Giappone 42
ZA - Sudafrica 40
EE - Estonia 31
FI - Finlandia 25
CH - Svizzera 24
KR - Corea 24
CI - Costa d'Avorio 23
BE - Belgio 18
BG - Bulgaria 18
AR - Argentina 14
JO - Giordania 13
PH - Filippine 13
IR - Iran 11
TR - Turchia 11
CA - Canada 10
IQ - Iraq 10
ES - Italia 9
ID - Indonesia 9
NG - Nigeria 9
SC - Seychelles 9
TH - Thailandia 9
BD - Bangladesh 8
PL - Polonia 8
MX - Messico 7
PK - Pakistan 7
EC - Ecuador 6
UZ - Uzbekistan 6
LB - Libano 5
PY - Paraguay 5
RO - Romania 4
TW - Taiwan 4
AT - Austria 3
EU - Europa 3
GR - Grecia 3
PT - Portogallo 3
SA - Arabia Saudita 3
AU - Australia 2
BA - Bosnia-Erzegovina 2
CL - Cile 2
CO - Colombia 2
EG - Egitto 2
HU - Ungheria 2
KE - Kenya 2
LT - Lituania 2
MA - Marocco 2
MY - Malesia 2
NO - Norvegia 2
NP - Nepal 2
PE - Perù 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BO - Bolivia 1
BY - Bielorussia 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
IL - Israele 1
KG - Kirghizistan 1
KY - Cayman, isole 1
LU - Lussemburgo 1
MK - Macedonia 1
NE - Niger 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
TN - Tunisia 1
UY - Uruguay 1
Totale 6.623
Salva come PNG Salva come JPEG
Città #
Southend 429
Singapore 374
Ashburn 273
Fairfield 267
Chandler 201
Woodbridge 155
Dong Ket 154
San Jose 124
Hong Kong 122
Seattle 122
Houston 121
Wilmington 121
Ann Arbor 113
Ho Chi Minh City 112
Santa Clara 96
Cambridge 91
Princeton 85
Beijing 83
Hanoi 76
Dublin 70
Hefei 63
Boardman 57
Lomé 51
Nanjing 48
New York 43
Jacksonville 42
Lauterbourg 40
Westminster 39
Padova 37
Tokyo 37
Los Angeles 34
Turin 32
Berlin 28
Bologna 25
Abidjan 23
Frankfurt am Main 23
Milan 23
Bern 22
Helsinki 22
Saint Petersburg 22
Shenyang 22
Buffalo 21
Florence 19
Seoul 19
Dallas 18
Bremen 17
Changsha 17
Sofia 17
Da Nang 16
Brussels 15
Hebei 15
Haiphong 14
Amman 13
Jinan 13
Guangzhou 12
London 11
Redondo Beach 11
Jiaxing 10
Medford 9
Munich 9
Nanchang 9
San Diego 9
Shanghai 9
Abeokuta 8
São Paulo 8
Bengaluru 7
Des Moines 7
Haikou 7
Mülheim 7
Norwalk 7
Orem 7
Rome 7
The Dalles 7
Verona 7
Brooklyn 6
Chengdu 6
Mahé 6
Paris 6
Tianjin 6
Biên Hòa 5
Chicago 5
Kyiv 5
Olalla 5
Phoenix 5
Redmond 5
Wuhan 5
Xi'an 5
Zhengzhou 5
Baghdad 4
Boston 4
Bến Tre 4
Chennai 4
Falkenstein 4
Farra d'Isonzo 4
Fuzhou 4
Huế 4
Hải Dương 4
Jakarta 4
Johannesburg 4
Lahore 4
Totale 4.427
Salva come PNG Salva come JPEG
Nome #
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 233
First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. 217
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. 208
Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas 206
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 206
No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response? 203
Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts 190
A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1 188
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 185
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 182
Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study 181
Prompt resolution of nasal aspergillosis with intranasal instillation of liposomal amphotericin-B (amBisome) and granulocyte transfusions 175
Molecular and cytogenetic characterization of a new case of t(5;17)(q35;q21) variant acute promyelocytic leukemia 175
Leukemia and multi-drug resistance: too many mechanisms of drug resistance or too many doctors resistant? 170
Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation. 167
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia 166
Mesenchymal stromal cells (MSCs) induce ex vivo proliferation and erythroid commitment of cord blood haematopoietic stem cells (CB-CD34+ cells) 165
Digital PCR (dPCR) Overcomes the Limitations in Detection and in Quantification of Quantitative PCR (qPCR) and Reveals Different Levels of BCR-ABL1 Copies/µl Among the Chronic Myeloid Leukemia (CML) Patients Achieving Major (MR3.0) or DEEP (MR4.0, MR4.5 and MR5.0) Molecular Response with Tyrosin Kynase Inhibitors (TKIs) 157
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients 156
Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid leukemia treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO) 154
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin 154
Resolving the diagnostic dilemma of T-cell clonal expansion after hematopoietic stem cell transplantation in T-cell lymphoma patients by TCR-gamma next generation sequencing 154
Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives 151
Molecular monitoring to identify a threshold of CBFbeta/MYH11 transcript below which continuous complete remission of acute myeloid leukemia inv16 is likely. 149
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. 149
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years 147
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases 147
Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. 147
INTERMITTENT IMATINIB (INTERIM) TREATMENT IN PH+-CML ELDERLY PATIENTS IN STABLE COMPLETE CYTOGENETIC RESPONSE 145
Consolidation therapy for adult acute myeloid leukemia: A systematic analysis according to evidence based medicine 141
Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a prospective study. 140
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target? 140
Bcr-Abl kinase domain mutations and resistance in Ph+ acute lymphoblastic leukemia from the imatinib to the 2nd-generation TKI era 138
Soft tissue and skeletal involvement in FIP1L1-PDGFR-A positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission 135
Managing chronic myeloid leukemia for treatment-free remission: A proposal from the GIMEMA CML WP 124
Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation. 120
Molecular monitoring of acute myeloid leukemia associated with inv(16): Threshold of CBFβ/MYH11 transcript copy number above which relapse occurs and below which continuous complete remission is likely (multiple letters) [8] 117
The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients. 110
Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly 108
Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome. 98
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study 90
Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC 73
BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study 72
Two more inv(16) acute myeloid leukemia cases with infrequent CBFβ-MYH11 fusion transcript: Clinical and molecular findings [4] 65
Venetoclax plus hypomethylating agents as first salvage therapy for myeloid malignancies relapsing after allogeneic HSCT 39
Totale 6.737
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.736
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.736
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021273 0 0 0 0 0 0 0 0 0 32 29 212
2021/2022744 47 16 64 99 71 50 13 45 32 59 138 110
2022/2023945 111 148 39 123 57 67 28 53 159 14 109 37
2023/2024256 16 39 13 30 15 69 12 29 5 11 9 8
2024/2025825 18 109 68 50 183 32 101 12 1 58 20 173
2025/20261.786 139 166 174 115 216 141 161 66 457 151 0 0
Totale 6.737